Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
Single arm study of induction durvalumab (1500 mg IV) for 1 cycle (every 4 weeks),
administered prior to starting concurrent definitive chemoradiation, followed by
consolidation durvalumab (1500 mg IV every 4 weeks) for up to 12 cycles.
The study will include an initial safety run-in portion. Patients in the safety run-in will
be monitored through completion of induction durvalumab, chemoradiation, and 2 cycles of
consolidation durvalumab for assessment of safety prior to completion of enrollment.
Phase:
Phase 2
Details
Lead Sponsor:
Rachel Sanborn
Collaborators:
AstraZeneca Providence Cancer Center, Earle A. Chiles Research Institute